Commons Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Commons Capital’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39K	Hold	10,620	–	–	0.03%	93
2026 Q1	$32.6K	Sell	10,620 -1,870	-15%	-$7.23K	0.03%	82
2025 Q4	$51.1K	Sell	12,490 -106,818	-90%	-$529K	0.03%	109
2025 Q3	$582K	Buy	119,308 +1,786	+2%	+$9.38K	0.38%	54
2025 Q2	$595K	Buy	117,522 +8,426	+8%	+$41.4K	0.45%	48
2025 Q1	$577K	Buy	109,096 +576	+0.5%	+$4.2K	0.53%	42
2024 Q4	$734K	Sell	108,520 -7,439	-6%	-$50K	0.66%	35
2024 Q3	$764K	Buy	115,959 +4,852	+4%	+$34.8K	0.84%	26
2024 Q2	$833K	Buy	+111,107	New	+$969K	1%	23

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Commons Capital's RXRX Position: Q2 2026 in Review

Commons Capital held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 10,620 shares worth $39K. The position accounts for 0.03% of the portfolio, ranked #93.

Commons Capital first reported a position in RXRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $833K in Q2 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Commons Capital held 10,620 shares of Recursion Pharmaceuticals worth $39K as of Q2 2026.
Commons Capital left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up 0.03% of Commons Capital's portfolio in Q2 2026, its #93 holding.
Commons Capital first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Commons Capital's Recursion Pharmaceuticals position peaked at $833K in Q2 2024.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Commons Capital's 13F filing for Q2 2026, filed 30 Jul 2026.